NGM Biopharmaceuticals

two jiggsaw puzzles connected with drawn hands shaking on the two puzzles

Biotech

VC firm pens $608M deal to direct NGM MASH drug to rare disease

KdT Ventures has signed off a $608 million deal for NGM's phase 2-ready MASH drug, with the VC firm setting up a new company to house the therapy.

James Waldron Dec 19, 2024 10:30am

money funding financing bank

VC firm that took NGM private oversees biotech’s $122M series A

Jul 17, 2024 7:42am

NGM to go private as part of $135M buyout by VC firm Column

Feb 26, 2024 10:26am

tunnel light dark climb stuck hole

NGM hunts for light at end of tunnel with NASH trial

May 5, 2023 1:13pm

image of a few paragliders

Amarin CEO abruptly resigns—Chutes & Ladders

Apr 7, 2023 9:30am

transparent open honest clean wipe squeegee clear

NGM Bio CEO reveals what led to 33% head count reduction

Apr 5, 2023 9:55am